Sucraid® is the only FDA-approved enzyme replacement therapy indicated for the treatment of sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID), in adult and pediatric patients 5 months of age and older.
See if Sucraid® is right for your patients diagnosed
with CSID.
Figure 1. How Sucraid® is dispensed
Figure 2. Role of Sucraid® in the metabolism of sucrose and absorption of its metabolic byproducts glucose and fructose across small intestine microvilli
Sucraid® has been shown in clinical trials to be effective in the treatment of patients with CSID. The active ingredient in Sucraid® is sacrosidase, a sucrase enzyme replacement that catalyzes the hydrolysis of sucrose into glucose and fructose, thereby facilitating absorption from the small intestine into the bloodstream. Sacrosidase is a potent and robust enzyme; on a per milliliter basis, sacrosidase is approximately 100-fold more potent than endogenous sucrase.1 It has been shown to be stable when stored at 4°C.2
Although Sucraid® provides replacement therapy for deficient sucrase, it does not provide specific replacement therapy for deficient isomaltase.3 Therefore, Sucraid® does not metabolize dietary starches (for example, potato, bread, or pasta) and restricting starch in the diet may still be necessary to minimize symptoms in patients with CSID who are starch intolerant. When starting therapy with Sucraid®, patients who still have symptoms are advised to restrict dietary starch for two weeks and then gradually reintroduce starch while monitoring for gastrointestinal symptoms. Keeping a dietary diary for the first few weeks of therapy is also recommended.
